Prof Peter Johnson
MD FRCP FMedSci
Professor of Medical Oncology
Peter Johnson is Professor of Medical Oncology at the University of Southampton and since 2019, National Clinical Director for Cancer at NHS England. He was previously Chief Clinician for Cancer Research UK from 2008 to 2017, and a Trustee of the National Cancer Research Institute.
His research interests are in applied immunology and immunotherapy; lymphoma biology and precision medicine, and clinical trials. He has been Chief Investigator for trials ranging from first in human novel antibody therapeutics to international randomised studies. He has published extensively on cancer biology and treatment, on novel biomarkers and their clinical evaluation.
P.W.M. Johnson, M. Federico, A.A. Kirkwood, A. Fossa, L. Berkahn, A.M. Carella, F. D'Amore, G. Enblad, A. Franceschetto, M. Fulham, S. Luminari, M. O'Doherty, P. Patrick, T. Roberts, G. Sidra, L. Stevens, P. Smith, J. Trotman, Z. Viney, J.A. Radford, S.F. Barrington. Adapted Treatment Guided by Interim PET Scan in Advanced Hodgkin’s Lymphoma. New Engl J Med, 2016. 374:2419-29.
Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20(5):649-662
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398:1157-1169
iDx-LUNG - Integrating non-invasive diagnostics into NHSE Lung Health Checks Innovate UK 2020-2023 £3.4M